Background and objectives: Human parvovirus B19 (B19) has been reported to be detected in the sera of patients with acute or chronic hepatitis. The aim of this study was to investigate the prevalence of parvovirus B19 in patients with chronic hepatitis B virus (CHB) and hepatitis C virus (CHC) infection and understand its clinical significance. Materials and methods: Plasma samples from 40 adult chronic hepatitis patients (20 CHB and 20 CHC) and 20 healthy blood donors were investigated for antibodies to B19 (IgM and IgG both). Active viremia was confirmed in IgM positive patients by real time PCR for parvovirus B19. Results: IgG antibodies to B19 were seen in 5 (25%) CHB, 10 (50%) CHC and 10(50%) healthy controls. IgM antibodies to B19 were seen in 3 (15%) CHB, 5 (25%) CHC and 1 (5%) controls. The liver dysfunction was significantly higher in B19 co-infected CHB patients. The serum ALT levels (Median 416.0, IQR 64.0-496.6 IU/L) and AST levels (Median 325, IQR 61.00- 380.00 IU/L) among B19 co-infected CHB patients were significantly higher than serum ALT levels (Median 43.0, IQR 33.0-61.5 IU/L) (p=0.023) and serum AST levels (Median 31 (26.50-53.00) IU/L) (p=0.013) in CHB mono-infected patients However the difference in serum bilirubin levels was not significant amongst the two groups (p=0.25). No aggravation of liver dysfunction was seen in B19 co-infected CHC patients. Interpretation and conclusions: Parvovirus B19 is prevalent equally amongst HBV, HCV infected and healthy population. Co-infection of B19 with HCV did not increase the frequency of liver dysfunction but it definitely aggravates the liver dysfunction in CHB co-infected patients.